Pierre Mugnier
About Pierre Mugnier
Pierre Mugnier is the Vice President of Global Regulatory Sciences for Cardiovascular & Neuroscience at Bristol Myers Squibb, with extensive experience in the pharmaceutical industry and regulatory affairs.
Current Position at Bristol Myers Squibb
Pierre Mugnier holds the position of Vice President of Global Regulatory Sciences for Cardiovascular & Neuroscience at Bristol Myers Squibb, based in Lawrence, New Jersey, United States. His role involves overseeing regulatory strategies and operations for these therapeutic areas.
Previous Roles at AstraZeneca and Bristol-Myers Squibb
Pierre previously served as Executive Regulatory Science Director for Cardiovascular, Renal, Metabolism, and Neuroscience at AstraZeneca in Gothenburg, Sweden, from 2019 to 2021. He also held multiple regulatory strategy roles at Bristol-Myers Squibb, including Regulatory Strategist for Innovative Medicine Development and Cardiovascular & Metabolism Therapeutic Area Lead.
Experience at Sanofi
Pierre worked at Sanofi in various capacities, including Director of Global Regulatory Affairs for Diabetes, Senior Manager of Corporate Regulatory Affairs, and Laboratory Head for the Infectious Disease Group. His tenure at Sanofi was marked by involvement in regulatory and discovery roles in both Bridgewater, New Jersey, and the Paris Area, France.
Post-Doctoral Research at University of Kent
Between 1997 and 1999, Pierre served as a Post-Doctoral Research Associate in the Department of Biosciences at the University of Kent in Canterbury, United Kingdom. This role involved research in the biosciences field, contributing to his strong scientific foundation.
Educational Background
Pierre studied at Paris-Sud University (Paris XI), where he earned a Doctor of Philosophy (PhD) in Medical Microbiology and Bacteriology from 1992 to 1996. Additionally, he achieved a Doctor of Pharmacy (PharmD) with a focus on Bacterial Resistance to Antibiotics between 1985 and 1996.
Industry Experience and Expertise
Pierre has fifteen years of experience in the pharmaceutical industry, encompassing roles from discovery to the registration of new products. He has eleven years specifically in global regulatory affairs across various therapeutic areas, demonstrating extensive expertise in drug and device regulatory workstreams. He has managed multidisciplinary and multinational regulatory projects, supported by a robust scientific background.